Blood dendritic cells generated with Flt3 ligand and CD40 ligand prime CD8+ T cells efficiently in cancer patients

Journal of Immunotherapy

Volumn 29, Issue 5, 2006, Pages 499-511

  Davis, Ian D ^a,b,e   Chen, Qiyuan ^a   Morris, Leone ^a   Quirk, Juliet ^a   Stanley, Maureen ^a   Tavarnesi, Maria L ^a   Parente, Phillip ^a   Cavicchiolo, Tina ^b   Hopkins, Wendie ^a   Jackson, Heather ^a   Dimopoulos, Nektaria ^a   Tai, Tsin Yee ^a   MacGregor, Duncan ^a,b   Browning, Judy ^a,b   Svobodová, Suzanne ^a,b   Caron, Dania ^d   Maraskovsky, Eugene ^a,c   Old, Lloyd J ^e   Chen, Weisan ^a   Cebon, Jonathan ^a,b  

^a LUDWIG INSTITUTE FOR CANCER RESEARCH   (Australia)

^b AUSTIN HEALTH   (Australia)

^c CSL LIMITED   (Australia)

^d AMGEN INC   (United States)

^e LUDWIG INSTITUTE FOR CANCER RESEARCH   (Australia)

Author keywords

Cancer; CD40 ligand; Dendritic cells; Flt3 ligand; Peptides; Vaccines

Indexed keywords

CD40 LIGAND; CD8 ANTIGEN; CD83 ANTIGEN; FLT3 LIGAND; HEPATITIS B CORE ANTIGEN; HLA DR ANTIGEN; INFLUENZA MATRIX PROTEIN; MELANOMA ANTIGEN; MELANOMA ANTIGEN 10; MELANOMA ANTIGEN 4; NY ESO 1 ANTIGEN; PEPTIDE; T LYMPHOCYTE RECEPTOR; UNCLASSIFIED DRUG;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIGEN SPECIFICITY; ARTHRALGIA; ARTICLE; AUTOIMMUNE DISEASE; BACKACHE; CANCER IMMUNOTHERAPY; CELL ACTIVATION; CELL INFILTRATION; CELL ISOLATION; CLINICAL ARTICLE; CLINICAL TRIAL; COMMON COLD; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DENDRITIC CELL; DRUG ERUPTION; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; GOITER; GRAVES DISEASE; HUMAN; HUMAN TISSUE; IMMUNE RESPONSE; LETHARGY; LYMPHOCYTOPENIA; MALE; MELANOMA; MONOCYTOSIS; MUSCLE CRAMP; NEUTROPENIA; NEUTROPHILIA; PRIORITY JOURNAL; PRURITUS; RHINITIS; SKIN MANIFESTATION; SORE THROAT; STATISTICAL SIGNIFICANCE; SWELLING; SYNOVITIS; T LYMPHOCYTE; UPPER RESPIRATORY TRACT INFECTION; UPREGULATION; VASCULITIS;

ADULT; ANTIGEN PRESENTATION; ANTIGENS, CD8; CANCER VACCINES; CD40 LIGAND; CD8-POSITIVE T-LYMPHOCYTES; CELLS, CULTURED; CYTOTOXICITY, IMMUNOLOGIC; DENDRITIC CELLS; FEMALE; HUMANS; IMMUNOTHERAPY, ADOPTIVE; LEUKAPHERESIS; LYMPHOCYTE ACTIVATION; MALE; MELANOMA; MEMBRANE PROTEINS; MIDDLE AGED; PEPTIDES; PILOT PROJECTS; RECEPTORS, ANTIGEN, T-CELL; SKIN NEOPLASMS;

EID: 33646079577     PISSN: 15249557     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.cji.0000211299.29632.8c     Document Type: Article

References (45)

1. Chapman J, Webster W. Cancer report. Vol. 2004: Australia and New Zealand Dialysis and Transplant Registry (ANZDATA); 2002.
2. Shackleton MJ, Sturrock S, MacGregor D, et al. Indolent Patterns of Disease Progression in Melanoma Patients Expressing anti-NY-ESO-1 antibodies. Cancer Immunosurveillance 1999. New York, NY: Cancer Research Institute; 1999:P1-09.
3. Davis ID, Jefford M, Parente P, et al. Rational approaches to human cancer immunotherapy. J Leukoc Biol. 2003;73:3-29.
4. Pardoll D. Does the immune system see tumors as foreign or self? Annu Rev Immunol. 2003;21:807-839.
5. Scanlan MJ, Simpson AJ, Old LJ. The cancer/testis genes: review, standardization, and commentary. Cancer Immun. 2004;4:1-15.
6. Jäger E, Gnjatic S, Nagata Y, et al. Induction of primary NY-ESO-1 immunity: CD8+ T lymphocyte and antibody responses in peptide-vaccinated patients with NY-ESO-1+ cancers. Proc Natl Acad Sci USA. 2000;97:12198-12203.
7. Coulie PG, Karanikas V, Colau D, et al. A monoclonal cytolytic T-lymphocyte response observed in a melanoma patient vaccinated with a tumor-specific antigenic peptide encoded by gene MAGE-3. Proc Natl Acad Sci USA. 2001;98:10290-10295.
8. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature. 1998;392:245-252.
9. Ferlazzo G, Munz C. NK cell compartments and their activation by dendritic cells. J Immunol. 2004;172:1333-1339.
10. Inaba K, Metlay JP, Crowley MT, et al. Dendritic cells pulsed with protein antigens in vitro can prime antigen-specific, MHC-restricted T cells in situ. J Exp Med. 1990;172:631-640.
11. Romani N, Koide S, Crowley M, et al. Presentation of exogenous protein antigens by dendritic cells to T cell clones. Intact protein is presented best by immature, epidermal Langerhans cells. J Exp Med. 1989;169:1169-1178.
12. Nouri-Shirazi M, Banchereau J, Bell D, et al. Dendritic cells capture killed tumor cells and present their antigens to elicit tumor-specific immune responses. J Immunol. 2000;165:3797-3803.
13. Jefford M, Maraskovsky E, Cebon J, et al. The use of dendritic cells in cancer therapy. Lancet Oncol. 2001;2:343-353.
14. Thurner B, Roder C, Dieckmann D, et al. Generation of large numbers of fully mature and stable dendritic cells from leukapheresis products for clinical application. J Immunol Methods. 1999;223:1-15.
15. Berger TG, Feuerstein B, Strasser E, et al. Large-scale generation of mature monocyte-derived dendritic cells for clinical application in cell factories. J Immunol Methods. 2002;268:131-140.
16. Randolph GJ, Beaulieu S, Lebecque S, et al. Differentiation of monocytes into dendritic cells in a model of transendothelial trafficking. Science. 1998;282:480-483.
17. Jefford M, Schnurr M, Toy T, et al. Functional comparison of DC generated in vivo with Flt3 ligand or in vitro from blood monocytes: differential regulation of function by specific classes of physiologic stimuli. Blood. 2003;102:1753-1763.
18. Namikawa R, Muench MO, Roncarolo MG. Regulatory roles of the ligand for Flk2/Flt3 tyrosine kinase receptor on human hematopoiesis. Stem Cells. 1996;14:388-395.
19. Maraskovsky E, Daro E, Roux E, et al. In vivo generation of human dendritic cell subsets by Flt3 ligand. Blood. 2000;96:878-884.
20. Lynch DH, Andreasen A, Maraskovsky E, et al. Flt3 ligand induces tumor regression and antitumor immune responses in vivo. Nat Med. 1997;3:625-631.
21. Shackleton M, Davis ID, Hopkins W, et al. The impact of imiquimod, a Toll-like receptor-7 ligand (TLR7L), on the immunogenicity of melanoma peptide vaccination with adjuvant Flt3 ligand. Cancer Immun. 2004;4:9.
22. Schoenberger SP, Toes REM, van der Voort EIH, et al. T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature. 1998;393:480-483.
23. Bennett SRM, Carbone FR, Karamalis F, et al. Help for cytotoxic-T-cell responses is mediated by CD40 signalling. Nature. 1998;393:478-480.
24. Ridge JP, Rosa FD, Matzinger P. A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell. Nature. 1998;393:474-478.
25. Fujii S, Liu K, Smith C, et al. The linkage of innate to adaptive immunity via maturing dendritic cells in vivo requires CD40 ligation in addition to antigen presentation and CD80/86 costimulation. J Exp Med. 2004;199:1607-1618.
26. Luft T, Jefford M, Luetjens P, et al. IL-1 beta enhances CD40 ligand-mediated cytokine secretion by human dendritic cells (DC): a mechanism for T cell-independent DC activation. J Immunol. 2002;168:713-722.
27. Luft T, Luetjens P, Hochrein H, et al. IFN-alpha enhances CD40 ligand-mediated activation of immature monocyte-derived dendritic cells. Int Immunol. 2002;14:367-380.
28. Mosca PJ, Hobeika AC, Colling K, et al. Multiple signals are required for maturation of human dendritic cells mobilized in vivo with Flt3 ligand. J Leukoc Biol. 2002;72:546-553.
29. Davis ID, Lotze MT. Melanoma peptide clinical trials. In: Kast WM, ed. Peptide-Based Cancer Vaccines. Austin: Eurekah.com; 2000:215-236.
30. Phan GQ, Yang JC, Sherry RM, et al. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci USA. 2003;100:8372-8377.
31. Jackson HM, Dimopoulos N, Chen Q, et al. A robust human T-cell culture method suitable for monitoring CD8+ and CD4+ T-cell responses from cancer clinical trial samples. J Immunol Methods. 2004;291:51-62.
32. Chen W, Yewdell JW, Levine RL, et al. Modification of cysteine residues in vitro and in vivo affects the immunogenicity and antigenicity of major histocompatibility complex class I-restricted viral determinants. J Exp Med. 1999;189:1757-1764.
33. Davis ID, Chen W, Jackson H, et al. Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4+ and CD8+ T cell responses in humans. Proc Natl Acad Sci USA. 2004;101:10697-10702.
34. Chen Q, Jackson H, Parente P, et al. Immunodominant CD4+ responses identified in a patient vaccinated with full-length NY-ESO-1 formulated with ISCOMATRIX adjuvant. Proc Natl Acad Sci USA. 2004;101:9363-9368.
35. Pulendran B, Banchereau J, Burkeholder S, et al. Flt3-ligand and granulocyte colony-stimulating factor mobilize distinct human dendritic cell subsets in vivo. J Immunol. 2000;165:566-572.
36. Matyszak MK, Citterio S, Rescigno M, et al. Differential effects of corticosteroids during different stages of dendritic cell maturation. Eur J Immunol. 2000;30:1233-1242.
37. Dutoit V, Rubio-Godoy V, Dietrich PY, et al. Heterogeneous T-cell response to MAGE-A10(254-262): high avidity-specific cytolytic T lymphocytes show superior antitumor activity. Cancer Res. 2001;61:5850-5856.
38. Thomas R, Chambers M, Boytar R, et al. Immature human monocyte-derived dendritic cells migrate rapidly to draining lymph nodes after intradermal injection for melanoma immunotherapy. Melanoma Res. 1999;9:474-481.
39. Serrano A, Lethe B, Delroisse JM, et al. Quantitative evaluation of the expression of MAGE genes in tumors by limiting dilution of cDNA libraries. Int J Cancer. 1999;83:664-669.
40. Rimoldi D, Salvi S, Reed D, et al. cDNA and protein characterization of human MAGE-10. Int J Cancer. 1999;82:901-907.
41. Li J, Yang Y, Fujie T, et al. Expression of the MAGE gene family in human gastric carcinoma. Anticancer Res. 1997;17:3559-3563.
42. Lin J, Lin L, Thomas DG, et al. Melanoma-associated antigens in esophageal adenocarcinoma: identification of novel MAGE-A10 splice variants. Clin Cancer Res. 2004;10:5708-5716.
43. Sugita M, Geraci M, Gao B, et al. Combined use of oligonucleotide and tissue microarrays identifies cancer/testis antigens as biomarkers in lung carcinoma. Cancer Res. 2002;62:3971-3979.
44. Valmori D, Dutoit V, Rubio-Godoy V, et al. Frequent cytolytic T-cell responses to peptide MAGE-A10(254-262) in melanoma. Cancer Res. 2001;61:509-512.
45. Chianese-Bullock KA, Pressley J, Garbee C, et al. MAGE-A1-, MAGE-A10-, and gp100-derived peptides are immunogenic when combined with granulocyte-macrophage colony-stimulating factor and montanide ISA-51 adjuvant and administered as part of a multipeptide vaccine for melanoma. J Immunol. 2005;174:3080-3086.